Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rasi

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Allergy|July 1, 1997
Who benefits from immunotherapy?S Bonini, G Rasi
Anticancer Research|July 1, 1996
A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP)--a possible new tumor markerE Garaci, P Sinibaldi, G Rasi
Tropenmedizin Und Parasitologie|September 1, 1979
IgE serum levels in urinary schistosomiasisM Nuti, G Rasi, L Simoni, et al.
International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association|June 1, 1982
IgE in leprosyM Nuti, G Rasi, C Rosa, et al.
International Journal of Immunopharmacology|January 4, 2001
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical applicationE Garaci, F Pica, G Rasi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2010
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providersP Russo, F S Mennini, P D Siviero, et al.
Anticancer Research|December 22, 1998
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanomaF Pica, M Fraschetti, C Matteucci, et al.
Anticancer Research|March 1, 1996
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trialF Salvati, G Rasi, L Portalone, et al.
Mechanisms of Ageing and Development|June 1, 1997
Combination therapy with BRMs in cancer and infectious diseasesE Garaci, F Pica, G Rasi, et al.
International Immunopharmacology|July 16, 2003
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinomaG Rasi, P Pierimarchi, P Sinibaldi Vallebona, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Allergy|July 1, 1997
Who benefits from immunotherapy?S Bonini, G Rasi
Anticancer Research|July 1, 1996
A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP)--a possible new tumor markerE Garaci, P Sinibaldi, G Rasi
Tropenmedizin Und Parasitologie|September 1, 1979
IgE serum levels in urinary schistosomiasisM Nuti, G Rasi, L Simoni, et al.
International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association|June 1, 1982
IgE in leprosyM Nuti, G Rasi, C Rosa, et al.
International Journal of Immunopharmacology|January 4, 2001
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical applicationE Garaci, F Pica, G Rasi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2010
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providersP Russo, F S Mennini, P D Siviero, et al.
Anticancer Research|December 22, 1998
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanomaF Pica, M Fraschetti, C Matteucci, et al.
Anticancer Research|March 1, 1996
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trialF Salvati, G Rasi, L Portalone, et al.
Mechanisms of Ageing and Development|June 1, 1997
Combination therapy with BRMs in cancer and infectious diseasesE Garaci, F Pica, G Rasi, et al.
International Immunopharmacology|July 16, 2003
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinomaG Rasi, P Pierimarchi, P Sinibaldi Vallebona, et al.
Pageof 4